Australia markets closed

Microba Life Sciences Limited (MAP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.3400+0.0100 (+3.03%)
At close: 02:52PM AEDT
Full screen
Previous close0.3300
Bid0.3400 x N/A
Ask0.3500 x N/A
Day's range0.3350 - 0.3400
52-week range0.1350 - 0.4500
Avg. volume392,414
Market cap125.436M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.52
  • Business Wire

    Microba Launches Next Generation Healthcare Testing

    BRISBANE, Australia, February 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba"), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.

  • Business Wire

    Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership

    BRISBANE, Australia, November 29, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) ("Sonic") has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Micr

  • Business Wire

    SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

    BRISBANE, Australia, October 27, 2022--SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.